DÄ internationalArchive12/2007Diagnosis and Treatment of Non-Muscle-Invasive Urothelial Carcinomas

Review article

Diagnosis and Treatment of Non-Muscle-Invasive Urothelial Carcinomas

Dtsch Arztebl 2007; 104(12): A-797

Dorp, F v; Kausch, I; Jocham, D

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Herr HW, Donat SM, Dalbagni G: Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002;168: 978–80. MEDLINE
2. Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, Schmeller N, Kriegmair M, Hofstetter A, Knüchel R: Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 15 2002; 95: 1234–8. MEDLINE
3. Jocham D, Witjes F, Wagner S et al.: Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862–6. MEDLINE
4. Tyrkus M, PowellI, Fakr W: Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications. J Urol 1992; 148: 44–6. MEDLINE
5. RUTT (1985) Essener Harnwegstumorregister.
6. Rübben H, Bubenzer J, Bokenkamp K, Lutzeyer W, Rathert P: Grading of transitional cell tumors of the urinary tract by urine cytology Urol Res 1979; 7: 83–91. MEDLINE
7. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PMM, Kurth KH: Tumor markers in the diagnosis of primary bladder cancer. A systemic review. J Urol 2003; 169: 1975–82. MEDLINE
8. Poulakis V, Witzsch U, De Vries HM: A comparison of nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 2001; 88: 692–701. MEDLINE
9. Steiner G, Schoenberg MP, Linn JF et al.: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997; 3: 621–4. MEDLINE
10. Halling KC, King W, Sokolova IA: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion for the detection of urothelial carcinoma in urine. J Urol 2002; 167: 2001–6. MEDLINE
11. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer JAMA 2001; 285: 324–8. MEDLINE
12. Boman H, Hedelin H, Jacobsson S, Holmang S: Newly disgnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 2002; 168: 1955–9. MEDLINE
13. Miladi M, Peyromaure M, Zerlib M, Saighi D, Debre B: The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003; 43: 241–3. MEDLINE
14. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM: Stage T1 bladder cancer grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28. MEDLINE
15. Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R: Radikale Zystektomie – Oft zu spät? Akt Urol 1986; 17: 234.
16. Herr HW, Sogani PC: Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166: 1296–9. MEDLINE
17. Chakravarti A, Winter K, Wu CL, Kaufmann D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W: Expression of the epidermal growth factor receptor and Her-2 are predictors of favourable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology group. Int J Radiat Oncol Biophys 2005; 62: 309–17. MEDLINE
18. Sylvester R, Oosterlinck W, van der Meijden A: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A metaanalysis of published results of randomized clinical trials. J Urol 2004; 171: 2186–90. MEDLINE
19. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD: A systemic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88: 209–16. MEDLINE
20. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124–9. MEDLINE
21. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group: Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44: 429–34. MEDLINE
22. Sylvester RJ, v.d. Mejiden, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer-a combined analysis of the published results of randomised clinical trials J Urol 2002; 168: 1964–70. MEDLINE
23. Hassan JM, Cookson MS, Smith JA Jr, Johnson DL, Chang SS: Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol 2004; 172: 882–4. MEDLINE
e1. Schmidtbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group: Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171: 135–8. MEDLINE
e2. Zaak D, Karl A, Knüchel R, Stepp H, Hartmann A, Reich O, Bachmann A, Siebels M, Popken G, Stief C: Diagnosis of urothelial carcinoma in situ of the bladder using fluorescence endoscopy. BJU Int 2005; 96: 217–22. MEDLINE
e3. Koss LG, Deitch D, Ramanathan R, Sherman AB: Diagnostic value of cytology of voided urine. Acta Cytol 1985; 29: 810–6. MEDLINE
e4. Gregoire M, Fradet Y, Meyer F, Tetu B, Bois R, Bedard G, Charrois R, Naud A: Diagnostic accuracy of urinary cytology and desoxyribonucleic acid flow cytometry and cytology on bladder washings during follow-up for bladder tumors. J Urol 1997; 157: 1660–4. MEDLINE
e5. Sarosdy MF, Hudson MA, Ellis WJ et al.: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997; 50: 349–53. MEDLINE
e6. Wiener HG, Mian CH, Haitel A et al.: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 159: 1876–80. MEDLINE
e7. Mao L, Schoenberg MP, Scicchitano M et al.: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659–62. MEDLINE
e8. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581–9. MEDLINE
e9. Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM: Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci 2002; 7: E36–E41. MEDLINE
e10. Schroeder GL, Lorenzo Gomez MF, Hautmann SH, Friedrich MG, Ekici S, Huland H, Lokeshwar VB: A side-by-side comparison of cytology and biomarkers, HA-HAse, hematuria detection, BTA STAT, UBC-Rapid for bladder cancer detection. J Urol 2004; 172: 1123–6. MEDLINE
e11. Bouffioux C, Kurth KH, Bono A et al.: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomised trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995; 153: 934–41. MEDLINE